{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T04:25:39Z","timestamp":1794803139303,"version":"4.9.1"},"reference-count":62,"publisher":"Portland Press Ltd.","issue":"1","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,28]]},"abstract":"<jats:p>Intrahepatic cholestasis is the main feature of a group of liver diseases that are characterized by hepatic and systemic accumulation of bile acids due to impaired excretion of bile, based on inflammation of intrahepatic and extrahepatic bile ducts or dysfunction of hepatobiliary transport proteins. The nuclear bile acid sensor farnesoid X receptor (FXR) is central for the regulation of bile acid turnover, including synthesis, hepatic excretion and intestinal and hepatic uptake. Several drugs targeting FXR have been developed for the treatment of cholestatic liver diseases, and so far one of them has been granted conditional approval. In this review, we will discuss the current knowledge and the clinical and experimental data available on agents affecting FXR and bile acid turnover.<\/jats:p>","DOI":"10.1042\/bst20210658","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T13:33:43Z","timestamp":1645536823000},"page":"361-373","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders"],"prefix":"10.1042","volume":"50","author":[{"given":"Antonio","family":"Molinaro","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden"},{"name":"Department of Molecular and Clinical Medicine\/Wallenberg Laboratory, University of Gothenburg, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-3085","authenticated-orcid":false,"given":"Hanns-Ulrich","family":"Marschall","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden"},{"name":"Department of Molecular and Clinical Medicine\/Wallenberg Laboratory, University of Gothenburg, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"2022030117242495200_BST-2021-0658CC1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","year":"2013","journal-title":"Cell Metab."},{"key":"2022030117242495200_BST-2021-0658CC2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","article-title":"Role of bile acids in metabolic control","volume":"29","year":"2018","journal-title":"Trends Endocrinol Metab."},{"key":"2022030117242495200_BST-2021-0658CC3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","year":"2016","journal-title":"Cell Metab."},{"key":"2022030117242495200_BST-2021-0658CC4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/0014-5793(91)80688-Y","article-title":"The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man","volume":"284","year":"1991","journal-title":"FEBS Lett."},{"key":"2022030117242495200_BST-2021-0658CC5","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","year":"2016","journal-title":"J. Lipid Res."},{"key":"2022030117242495200_BST-2021-0658CC6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1194\/jlr.RA119000243","article-title":"A human-like bile acid pool induced by deletion of hepatic Cyp2c70 modulates effects of FXR activation in mice","volume":"61","year":"2020","journal-title":"J. Lipid Res."},{"key":"2022030117242495200_BST-2021-0658CC7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/cphy.c120027","volume":"3","year":"2013","journal-title":"Compr. Physiol."},{"key":"2022030117242495200_BST-2021-0658CC8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jhep.2021.02.011","article-title":"Bile formation and secretion: an update","volume":"75","year":"2021","journal-title":"J. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC9","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1194\/jlr.R900012-JLR200","article-title":"Bile acid transporters","volume":"50","year":"2009","journal-title":"J. Lipid Res."},{"key":"2022030117242495200_BST-2021-0658CC10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","article-title":"Global chemical effects of the microbiome include new bile-acid conjugations","volume":"579","year":"2020","journal-title":"Nature"},{"key":"2022030117242495200_BST-2021-0658CC11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-020-2396-4","article-title":"A metabolic pathway for bile acid dehydroxylation by the gut microbiome","volume":"582","year":"2020","journal-title":"Nature"},{"key":"2022030117242495200_BST-2021-0658CC12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","year":"2013","journal-title":"Cell Metab."},{"key":"2022030117242495200_BST-2021-0658CC13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-021-03832-5","article-title":"Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians","volume":"599","year":"2021","journal-title":"Nature"},{"key":"2022030117242495200_BST-2021-0658CC14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","year":"1999","journal-title":"Science"},{"key":"2022030117242495200_BST-2021-0658CC15","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","year":"1999","journal-title":"Science"},{"key":"2022030117242495200_BST-2021-0658CC16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","year":"1999","journal-title":"Mol. Cell"},{"key":"2022030117242495200_BST-2021-0658CC17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","year":"1995","journal-title":"Cell"},{"key":"2022030117242495200_BST-2021-0658CC18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","year":"2000","journal-title":"Cell"},{"key":"2022030117242495200_BST-2021-0658CC19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","year":"2000","journal-title":"Mol. Cell"},{"key":"2022030117242495200_BST-2021-0658CC20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","year":"2000","journal-title":"Mol. Cell"},{"key":"2022030117242495200_BST-2021-0658CC21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","year":"2005","journal-title":"Cell Metab."},{"key":"2022030117242495200_BST-2021-0658CC22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1101\/gad.184788.111","article-title":"Endocrine fibroblast growth factors 15\/19 and 21: from feast to famine","volume":"26","year":"2012","journal-title":"Genes Dev."},{"key":"2022030117242495200_BST-2021-0658CC23","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.bcp.2013.07.022","article-title":"Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition","volume":"86","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"2022030117242495200_BST-2021-0658CC24","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","year":"2015","journal-title":"J. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC25","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","year":"2018","journal-title":"Nat. Med."},{"key":"2022030117242495200_BST-2021-0658CC26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development","volume":"11","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"EASL","year":"2017","journal-title":"J. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"2022030117242495200_BST-2021-0658CC29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","year":"2006","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24691","article-title":"A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes","volume":"55","year":"2012","journal-title":"Hepatology"},{"key":"2022030117242495200_BST-2021-0658CC31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC32","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"2022030117242495200_BST-2021-0658CC33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases","volume":"51","author":"European Association for the Study of the Liver","year":"2009","journal-title":"J. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC34","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3748\/wjg.15.2049","article-title":"Intrahepatic cholestasis of pregnancy","volume":"15","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"2022030117242495200_BST-2021-0658CC35","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S0168-8278(00)80139-7","article-title":"Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management","volume":"33","year":"2000","journal-title":"J. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(18)31877-4","article-title":"Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"2022030117242495200_BST-2021-0658CC37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(19)31270-X","article-title":"Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"2022030117242495200_BST-2021-0658CC38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2468-1253(21)00074-1","article-title":"Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis","volume":"6","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC39","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","year":"2002","journal-title":"J. Med. Chem."},{"key":"2022030117242495200_BST-2021-0658CC40","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","year":"2015","journal-title":"Gastroenterology"},{"key":"2022030117242495200_BST-2021-0658CC41","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"2022030117242495200_BST-2021-0658CC42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2022030117242495200_BST-2021-0658CC43","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC44","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/hep4.1720","article-title":"Impact of obeticholic acid exposure on decompensation and mortality in primary biliary cholangitis and cirrhosis","volume":"5","year":"2021","journal-title":"Hepatol. Commun."},{"key":"2022030117242495200_BST-2021-0658CC45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","year":"2020","journal-title":"J. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC46","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","year":"2019","journal-title":"Hepatology"},{"key":"2022030117242495200_BST-2021-0658CC47","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","year":"2018","journal-title":"Hepatol. Commun."},{"key":"2022030117242495200_BST-2021-0658CC48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","year":"2019","journal-title":"J. Hepatol."},{"key":"2022030117242495200_BST-2021-0658CC49","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3389\/fphar.2018.00931","article-title":"Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH","volume":"9","year":"2018","journal-title":"Front. Pharmacol."},{"key":"2022030117242495200_BST-2021-0658CC50","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/apt.13457","article-title":"The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation","volume":"43","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2022030117242495200_BST-2021-0658CC51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","year":"2014","journal-title":"Hepatology"},{"key":"2022030117242495200_BST-2021-0658CC52","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","article-title":"Lysophosphatidic acid is a potential mediator of cholestatic pruritus","volume":"139","year":"2010","journal-title":"Gastroenterology"},{"key":"2022030117242495200_BST-2021-0658CC53","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions","volume":"56","year":"2012","journal-title":"Hepatology"},{"key":"2022030117242495200_BST-2021-0658CC54","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"2022030117242495200_BST-2021-0658CC55","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","year":"2019","journal-title":"Hepatol. Commun."},{"key":"2022030117242495200_BST-2021-0658CC56","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hep4.1244","article-title":"Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in alagille syndrome","volume":"2","year":"2018","journal-title":"Hepatol. Commun."},{"key":"2022030117242495200_BST-2021-0658CC57","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"2022030117242495200_BST-2021-0658CC58","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","article-title":"Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis","volume":"8","year":"2018","journal-title":"Sci. Rep."},{"key":"2022030117242495200_BST-2021-0658CC59","doi-asserted-by":"publisher","first-page":"e234185","DOI":"10.1136\/bcr-2019-234185","article-title":"Odevixibat and partial external biliary diversion showed equal improvement of cholestasis in a patient with progressive familial intrahepatic cholestasis","volume":"13","year":"2020","journal-title":"BMJ Case Rep."},{"key":"2022030117242495200_BST-2021-0658CC60","doi-asserted-by":"publisher","first-page":"101751","DOI":"10.1016\/j.clinre.2021.101751","article-title":"Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study","volume":"45","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"2022030117242495200_BST-2021-0658CC61","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/hep.28965","article-title":"The ascending pathophysiology of cholestatic liver disease","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"2022030117242495200_BST-2021-0658CC62","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s42255-021-00452-1","article-title":"Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling","volume":"3","year":"2021","journal-title":"Nat. Metab."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/50\/1\/361\/930427\/bst-2021-0658c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/50\/1\/361\/930427\/bst-2021-0658c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T17:24:39Z","timestamp":1646155479000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/50\/1\/361\/230820\/Bile-acid-metabolism-and-FXR-mediated-effects-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,22]]},"published-print":{"date-parts":[[2022,2,28]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20210658","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}